PA8429301A1 - BIARYLACETYLENE AS INHIBITORS OF MATRIX METALOPROTEASE. - Google Patents
BIARYLACETYLENE AS INHIBITORS OF MATRIX METALOPROTEASE.Info
- Publication number
- PA8429301A1 PA8429301A1 PA19978429301A PA8429301A PA8429301A1 PA 8429301 A1 PA8429301 A1 PA 8429301A1 PA 19978429301 A PA19978429301 A PA 19978429301A PA 8429301 A PA8429301 A PA 8429301A PA 8429301 A1 PA8429301 A1 PA 8429301A1
- Authority
- PA
- Panama
- Prior art keywords
- compounds
- disorders
- disease
- pharmaceutical compositions
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Steroid Compounds (AREA)
Abstract
SE PRESENTAN COMPUESTOS INHIBITORIOS DE LA METALOPROTEASA DE MATRIZ, COMPOSICIONES FARMACEUTICAS DE LOS MISMOS Y UN METODO PARA TRATAR ENFERMEDADES QUE EMPLEA DICHOS COMPUESTOS. LOS COMPUESTOS DE LA PRESENTE INVENCION TIENEN LA FORMULA GENERALIZADA: DONDE R15 ES SELECCIONADO ENTRE EL GRUPO QUE CONSISTE EN HOCH2 MEOCH2, (N-PR)2NCH2, CH3CO2CH2, ETOCO2CH2,HO(CH2)2, CH3CO2(CH2)2, HO2C(CH2)2, OHC(CH2)3, HO(CH2)4PH,3-HO-PH, Y PHCH2OCH2; Y R16 ES: ESTOS COMPUESTOS SON UTILES PARA INHIBIR LAS METALOPROTEASAS DE MATRIZ Y, POR LO TANTO, PARA COMBATIR LOS TRASTORNOS A LOS CUALES CONTRIBUYEN LAS MMP, TALES COMO LA OSTEOARTRITIS, LA ARTRITIS REUMATOIDEA, LA ARTRITIS SEPTICA, LAS ENFERMEDADES PERIODONTALES, LAS ULCERAS DE CORNEA, LA PROTEINURIA, LA ENFERMEDAD DE ANEURISMA AORTICO, LA EPIDERMOLISIS VESICULAR DISTROFICA, LOS TRASTORNOS QUE PRODUCEN RESPUESTAS INFLAMATORIAS, LAS OSTEOPENIAS EN LAS QUE MEDIA LA ACTIVIDAD DE MMP, LA ENFERMEDAD DE LA ARTICULACION TEMPOROMANDIBULAR, LAS ENFERMEDADES DESMIELINIZANTES DEL SISTEMA NERVIOSO; LAS METASTASIS DE TUMORES O LA PERDIDA DEGENERATIVA DE CARTILAGO POSTERIOR A LA LESION ARTICULAR TRAUMATICA, Y LA TROMBOSIS CORONARIA A PARTIR DE LA RUPTURA DE PLACA ATEROESCLEROTICA. LA PRESENTE INVENCION PRESENTA ASIMISMO COMPOSICIONES FARMACEUTICAS Y METODOS PARA TRATAR DICHOS TRASTORNOS.INHIBITORY COMPOUNDS OF MATRIX METALOPROTEASE, PHARMACEUTICAL COMPOSITIONS OF THE SAME, AND A METHOD FOR TREATING DISEASES THAT USE THESE COMPOUNDS ARE PRESENTED. THE COMPOUNDS OF THE PRESENT INVENTION HAVE THE GENERALIZED FORMULA: WHERE R15 IS SELECTED FROM THE GROUP THAT CONSISTS OF HOCH2 MEOCH2, (N-PR) 2NCH2, CH3CO2CH2, ETOCO2CH2, HO (CH2) 2, CH3CO2 (CH2) 2, HO2 ) 2, OHC (CH2) 3, HO (CH2) 4PH, 3-HO-PH, AND PHCH2OCH2; AND R16 IS: THESE COMPOUNDS ARE USEFUL FOR INHIBITING MATRIX METALLOPROTEASES AND THEREFORE, TO COMBAT DISORDERS TO WHICH MMP CONTRIBUTE, SUCH AS OSTEOARTHRITIS, RHEUMETHETIC ARTHRITIS, SEPTIAL URETHRITIS CORNEA, PROTEINURIA, AORTIC ANEURISM DISEASE, DYSSTROPHIC VESICULAR EPIDERMOLISIS, DISORDERS THAT PRODUCE INFLAMMATORY RESPONSES, OSTEOPENIAS IN THE ACTIVITY OF THE SLEEPING DISEASES, THE ILLNESS OF THE TEMPOROMARIUS DISEASE THE METASTASIS OF TUMORS OR THE DEGENERATIVE LOSS OF CARTILAGO AFTER TRAUMATIC ARTICULAR INJURY, AND CORONARY THROMBOSIS FROM THE RUPTURE OF ATEROSCLEROTIC PLATE. THE PRESENT INVENTION ALSO PRESENTS PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING SUCH DISORDERS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64502896A | 1996-05-15 | 1996-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8429301A1 true PA8429301A1 (en) | 2000-05-24 |
Family
ID=24587368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA19978429301A PA8429301A1 (en) | 1996-05-15 | 1997-05-12 | BIARYLACETYLENE AS INHIBITORS OF MATRIX METALOPROTEASE. |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP0912496A1 (en) |
JP (1) | JP3090957B2 (en) |
CN (1) | CN1139570C (en) |
AR (1) | AR007097A1 (en) |
AU (1) | AU710759B2 (en) |
BR (1) | BR9709077A (en) |
CA (1) | CA2253796C (en) |
CO (1) | CO5080759A1 (en) |
HN (1) | HN1997000088A (en) |
HR (1) | HRP970245B1 (en) |
ID (1) | ID16910A (en) |
PA (1) | PA8429301A1 (en) |
SV (1) | SV1997000035A (en) |
TN (1) | TNSN97084A1 (en) |
TW (1) | TW381079B (en) |
WO (1) | WO1997043245A1 (en) |
YU (1) | YU18697A (en) |
ZA (1) | ZA974031B (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6288063B1 (en) | 1998-05-27 | 2001-09-11 | Bayer Corporation | Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors |
AR035478A1 (en) * | 1999-01-27 | 2004-06-02 | Wyeth Corp | AMIDA-HYDROXAMIC ACID, ACETYLLENE, BETA-SULPHONAMIDE AND PHOSPHINIC ACID AS INHIBITORS OF TACE, USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITION CONTAINING THEM |
US6326516B1 (en) | 1999-01-27 | 2001-12-04 | American Cyanamid Company | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors |
EP1031349A1 (en) * | 1999-02-25 | 2000-08-30 | Bayer Aktiengesellschaft | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of cerebral diseases |
US7141607B1 (en) | 2000-03-10 | 2006-11-28 | Insite Vision Incorporated | Methods and compositions for treating and inhibiting retinal neovascularization |
CA2804918C (en) | 2010-07-08 | 2018-03-06 | Kaken Pharmaceutical Co., Ltd. | N-hydroxyformamide derivative and medicament containing same |
CN106458938A (en) | 2014-04-03 | 2017-02-22 | 拜耳制药股份公司 | Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof |
CA2944614A1 (en) | 2014-04-03 | 2015-10-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratoy tract diseases |
EP3126339A1 (en) | 2014-04-03 | 2017-02-08 | Bayer Pharma Aktiengesellschaft | 2,5-disubstituted cyclopentane carboxylic acids and use thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3784701A (en) * | 1970-09-21 | 1974-01-08 | American Cyanamid Co | Compositions containing substituted benzoylpropionic acids and method of use to treat inflammation and pain |
DE2112716A1 (en) * | 1971-03-17 | 1972-10-05 | Thomae Gmbh Dr K | Biphenylyl-butyric acid derivs. - anti phlogistics |
US5789434A (en) * | 1994-11-15 | 1998-08-04 | Bayer Corporation | Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors |
-
1997
- 1997-05-09 CO CO97025172A patent/CO5080759A1/en unknown
- 1997-05-09 ZA ZA9704031A patent/ZA974031B/en unknown
- 1997-05-09 TN TNTNSN97084A patent/TNSN97084A1/en unknown
- 1997-05-09 HR HR970245A patent/HRP970245B1/en not_active IP Right Cessation
- 1997-05-12 CA CA002253796A patent/CA2253796C/en not_active Expired - Fee Related
- 1997-05-12 HN HN1997000088A patent/HN1997000088A/en unknown
- 1997-05-12 EP EP97923622A patent/EP0912496A1/en not_active Withdrawn
- 1997-05-12 CN CNB971964564A patent/CN1139570C/en not_active Expired - Fee Related
- 1997-05-12 YU YU18697A patent/YU18697A/en unknown
- 1997-05-12 PA PA19978429301A patent/PA8429301A1/en unknown
- 1997-05-12 TW TW086106283A patent/TW381079B/en not_active IP Right Cessation
- 1997-05-12 JP JP09540980A patent/JP3090957B2/en not_active Expired - Fee Related
- 1997-05-12 WO PCT/US1997/007921 patent/WO1997043245A1/en not_active Application Discontinuation
- 1997-05-12 AR ARP970101977A patent/AR007097A1/en unknown
- 1997-05-12 BR BR9709077A patent/BR9709077A/en not_active Application Discontinuation
- 1997-05-12 SV SV1997000035A patent/SV1997000035A/en unknown
- 1997-05-12 AU AU29386/97A patent/AU710759B2/en not_active Ceased
- 1997-05-14 ID IDP971606A patent/ID16910A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2253796A1 (en) | 1997-11-20 |
CN1139570C (en) | 2004-02-25 |
CN1225623A (en) | 1999-08-11 |
HRP970245B1 (en) | 2002-06-30 |
ID16910A (en) | 1997-11-20 |
CO5080759A1 (en) | 2001-09-25 |
WO1997043245A1 (en) | 1997-11-20 |
HRP970245A2 (en) | 1998-04-30 |
SV1997000035A (en) | 1999-01-14 |
BR9709077A (en) | 1999-08-03 |
EP0912496A1 (en) | 1999-05-06 |
HN1997000088A (en) | 1997-06-18 |
JPH11511179A (en) | 1999-09-28 |
AU710759B2 (en) | 1999-09-30 |
AU2938697A (en) | 1997-12-05 |
ZA974031B (en) | 1998-02-19 |
AR007097A1 (en) | 1999-10-13 |
YU18697A (en) | 1999-11-22 |
TW381079B (en) | 2000-02-01 |
CA2253796C (en) | 2003-10-28 |
TNSN97084A1 (en) | 2005-03-15 |
JP3090957B2 (en) | 2000-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PA8429701A1 (en) | INHIBITION OF MATRIX METALOPROTEASES BY SUBSTITUTED BIARILOXOBUTIRIC ACIDS | |
PA8429301A1 (en) | BIARYLACETYLENE AS INHIBITORS OF MATRIX METALOPROTEASE. | |
PA8456801A1 (en) | DERIVATIVES OF ARILOXIARILSULFONILAMINO HIDROXAMICOS ACIDS | |
CN109152933A (en) | Induce the compound of degradation and application thereof of anti-apoptotic BCL-2 family protein | |
AR014261A1 (en) | BENZOTIAZEPINE HYPOLIPIDEMIC COMPOUNDS, COMPOSITIONS AND PROCESS FOR PREPARATION | |
AR007640A1 (en) | DERIVATIVES OF PHENYLALANINE, PROCEDURE TO PREPARE THEM, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM AND USE THEM TO PREPARE A MEDICINAL PRODUCT THAT ACTS AS AN INHIBITOR OF ALPHA INTEGRINE (v) | |
ES2062943B1 (en) | NEW DERIVATIVES OF (2-METHYL-3-PIRIDIL) CYANOMETILPIPERAZINES. | |
BR9811779A (en) | Tetrahydro prostaglandins are replaced by aromatic c16-c20 useful as fp agonists | |
BR9815596A (en) | Compound, pharmaceutical composition, method of treating inflammatory diseases and method of treating condition or disease mediated by mmps and / or tnf and / or agrecanase | |
ES2183332T3 (en) | AROMATIC BICYCLE AMINO ACIDS. | |
AR003473A1 (en) | USE OF L-CARNITINE OR AN ACIL L-CARNITINE WHERE THE ACIL IS SELECTED FROM THE GROUP WHICH INCLUDES ACETYL, PROPIONYL, BUTYRILE, VALERYL AND ISOVALERIL, OR A PHARMACOLOGICALLY ACCEPTABLE SALT FOR THE PRODUCTION OF THE SAME | |
PA8429801A1 (en) | INHIBITION OF MATRIX METALOPROTEASES BY SUBSTITUTED FENETILE COMPOUNDS | |
ID28365A (en) | NEW NATURAL PRODUCTS DOWN | |
PA8429401A1 (en) | SUBSTITUTED OXYBUTYRIC ACIDS AS MATRIX METALOPROTEASE INHIBITORS | |
BR9814913A (en) | New substance kf-1040 and process for producing it | |
AR002246A1 (en) | NEW SALTS FOR THE ADDITION OF CEFEM ACIDS PROCEDURES FOR THEIR PREPARATION, THE USE OF THE SAME FOR THE PREPARATION OF MEDICINES, AND THE PROCEDURE FOR THE PREPARATION OF SUCH MEDICINAL PRODUCT. | |
PA8429601A1 (en) | INHIBITION OF MATRIX METALOPROTEINASES BY ACIDS 2- (W-AROILALQUIL) -4-BIARIL-4-OXOBUTIRICOS. | |
NO844889L (en) | OKSICAM DERIVATIVES AND PROCEDURES FOR THEIR PREPARATION | |
ECSP972114A (en) | BIARYLACETYLENE AS INHIBITORS OF MATRIX METALOPROTEASE | |
AR248406A1 (en) | Substituted 4-sulphonylamino-2-azinyl-1,2,4-triazol-3-ones, process and intermediates for their preparation and their use as herbicides | |
ECSP972111A (en) | MATRIX METALOPROTEINASES INHIBITORS BY ACIDS 2- (AROILALQUIL) -4 BIARIL-4- OXOBUTIRICOS | |
PA8510601A1 (en) | ETERES OF CALCIUM DICARBOXYLATE, METHODS FOR THE PREPARATION AND TREATMENT OF VASCULAR DISEASES AND DIABETES WITH THE SAME | |
Follis Jr | A survey of bone disease | |
BRPI0414812A (en) | method of inhibiting the expression of multidrug resistant genes and inhibiting the production of proteins resulting from the expression of such genes, thereby improving the effectiveness of chemotherapeutic agents for treating cancer | |
Pastor et al. | Cytotoxicity and mitotic alterations induced by non-genotoxic lithium salts in CHO cells in vitro |